Ateptidase

PreclinicalProtein / enzyme

ZZhujiang Hospital

Ateptidase is one of 10 small molecule programs targeting Intracranial Hemorrhage. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intracranial HemorrhageActive, not recruiting

Intracranial HemorrhagePreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Intracranial Hemorrhage

#DrugCompanyPhaseTrials

Savaysa

Colcrys

Atorvastatin Calcium

1 4

Anticoagulants

Sanofi

Phase 3

1 5

Uloric

Takeda

Phase 2

1 6

Fresh Frozen Plasma

CSL Behring

Preclinical

2 7

Anticoagulant

Bayer

Preclinical

1 8

Antithrombotic Drugs

Bayer

Preclinical

1 9

Dabigatran Dose 2

Boehringer Ingelheim

Preclinical

1 10

Ateptidase

ZZhujiang Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Intracranial Hemorrhage1 trial

Relationships Among FVIII, t-PA/PAI-1, and MMP-9 Levels and Intracranial Hemorrhage Complications After Thrombolysis With Alteplase in Patients With Acute Ischemic Stroke: Protocol for a Multicenter Retrospective Study

Unknown status·ZZhujiang Hospital··NCT03733223·350 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ateptidase. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ateptidase compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ateptidase. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhujiang Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Preclinical[1]
Company: ZZhujiang Hospital

Ateptidase

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Intracranial Hemorrhage1 trial

References

Drug Info

Quick Facts

Related News